Qsymia

Marketing

FDA's promo police ding Vivus for misleading Qsymia webpage

In their second enforcement letter of 2019, the FDA's marketing overseers reprimanded Vivus for downplaying the risks of its weight loss drug Qsymia.
Beth Snyder Bulik Jun 6, 2019 12:43pm

Eisai obesity drug Belviq picks up heart-safety edge

Jul 18, 2018 10:28am

Novo preps big obesity push, undeterred by its rivals' fates

Nov 21, 2017 11:57am

Chasing a payday, new drugmakers favor solo launches: report

Apr 17, 2017 11:22am

Orexigen puts Contrave at risk by stopping yet another heart study

Apr 14, 2016 10:09am